{"id":17504,"date":"2026-01-23T15:22:08","date_gmt":"2026-01-23T20:22:08","guid":{"rendered":"https:\/\/eczemahelp.ca\/?p=17504"},"modified":"2026-02-17T15:28:26","modified_gmt":"2026-02-17T20:28:26","slug":"un-medecin-vous-parle-dopzelura-ruxolitinib","status":"publish","type":"post","link":"https:\/\/eczemahelp.ca\/fr\/un-medecin-vous-parle-dopzelura-ruxolitinib\/","title":{"rendered":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)"},"content":{"rendered":"<h2>Apprenez-en plus sur les inhibiteurs de JAK topiques contre la dermatite atopique avec la D<sup>re<\/sup> Ashley Sutherland, dermatologue<\/h2>\n<p><span style=\"font-weight: 400;\">La Soci\u00e9t\u00e9 canadienne de l\u2019ecz\u00e9ma a demand\u00e9 \u00e0 la D<\/span><span style=\"font-weight: 400;\"><sup>re<\/sup><\/span><span style=\"font-weight: 400;\">\u00a0Ashley Sutherland (M.\u00a0Sc., FRCPC), dermatologue, de nous faire part de son expertise au sujet d\u2019Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\"> (ruxolitinib), un inhibiteur de JAK topique, dans le traitement de la dermatite atopique (DA), soit la forme la plus courante d\u2019ecz\u00e9ma.<\/span><\/p>\n<h2>Que sont les inhibiteurs de JAK topiques?<\/h2>\n<p><span style=\"font-weight: 400;\">Les inhibiteurs topiques de Janus kinases (JAK) sont des cr\u00e8mes non st\u00e9ro\u00efdiennes utilis\u00e9es pour traiter la DA l\u00e9g\u00e8re ou mod\u00e9r\u00e9e chez les patients pour qui d&rsquo;autres traitements topiques (corticost\u00e9ro\u00efdes, inhibiteurs de la calcineurine) n\u2019ont pas \u00e9t\u00e9 efficaces ou lorsque ces traitements ne sont pas recommand\u00e9s. Les inhibiteurs de JAK topiques agissent en bloquant de nombreuses mol\u00e9cules, appel\u00e9es <\/span><i><span style=\"font-weight: 400;\">cytokines<\/span><\/i><span style=\"font-weight: 400;\">, qui aggravent l\u2019inflammation et les d\u00e9mangeaisons.<\/span><\/p>\n<h2>Comment Opzelura\u00ae<span style=\"font-weight: 400;\">\u00a0<\/span>agit-il?<\/h2>\n<p><span style=\"font-weight: 400;\">Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\">\u00a0cible la voie JAK\/STAT dans la peau, responsable des sympt\u00f4mes associ\u00e9s \u00e0 la DA. Il agit en bloquant de nombreuses mol\u00e9cules, appel\u00e9es <\/span><i><span style=\"font-weight: 400;\">cytokines<\/span><\/i><span style=\"font-weight: 400;\">, qui aggravent l\u2019inflammation et les d\u00e9mangeaisons<\/span><span style=\"font-weight: 400;\"><sup>1<\/sup><\/span><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2>Qui peut prendre Opzelura\u00ae?<span style=\"font-weight: 400;\">\u00a0<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\"> s\u2019applique sur la peau (voie topique) pour traiter les patients de 12\u00a0ans et plus atteints de dermatite atopique l\u00e9g\u00e8re ou mod\u00e9r\u00e9e, aussi appel\u00e9e <\/span><i><span style=\"font-weight: 400;\">ecz\u00e9ma<\/span><\/i><span style=\"font-weight: 400;\">. Il est utilis\u00e9 lorsque le traitement par d&rsquo;autres m\u00e9dicaments topiques sur ordonnance n\u2019a pas \u00e9t\u00e9 efficace ou n\u2019a pas \u00e9t\u00e9 bien tol\u00e9r\u00e9, ou lorsque ces m\u00e9dicaments ne devraient pas \u00eatre utilis\u00e9s<\/span><span style=\"font-weight: 400;\"><sup>1<\/sup><\/span><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2>Comment Opzelura\u00ae<span style=\"font-weight: 400;\">\u00a0<\/span>s&rsquo;utilise-t-il?<\/h2>\n<p><span style=\"font-weight: 400;\">Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\">\u00a0est une cr\u00e8me \u00e0 appliquer directement sur la peau. Son utilisation est s\u00fbre sur toutes les r\u00e9gions cutan\u00e9es. Toutefois, il ne doit pas \u00eatre appliqu\u00e9 dans les yeux, la bouche ou le vagin. Il faut \u00e9viter de l&rsquo;appliquer sur les l\u00e8vres pour \u00e9viter de l\u2019avaler par accident.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\"> doit g\u00e9n\u00e9ralement \u00eatre appliqu\u00e9 sur la peau deux fois par jour en p\u00e9riode de pouss\u00e9e, jusqu\u2019\u00e0 ce que l&rsquo;\u00e9tat de la peau s\u2019am\u00e9liore. Les patients doivent n\u00e9anmoins suivre les directives de leur professionnel de la sant\u00e9.<\/span><\/p>\n<h2>Quels sont les effets secondaires de ce m\u00e9dicament?<\/h2>\n<p><span style=\"font-weight: 400;\">Les effets secondaires possibles comprennent le rhume, les maux de t\u00eate, la grippe et la fi\u00e8vre. Vous pourriez <\/span>pr\u00e9senter <span style=\"font-weight: 400;\">les effets secondaires suivants \u00e0 l\u2019endroit o\u00f9 vous avez appliqu\u00e9 Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\">\u00a0: acn\u00e9, douleur (sensation de br\u00fblure ou de piq\u00fbre), d\u00e9mangeaisons, rougeur, \u00e9ruption cutan\u00e9e et exfoliation l\u00e9g\u00e8re (\u00e9limination des peaux mortes).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Les renseignements th\u00e9rapeutiques des inhibiteurs de JAK topiques d\u00e9livr\u00e9s sur ordonnance contiennent des mises en garde et pr\u00e9cautions importantes (en encadr\u00e9 noir), en fonction des types d\u2019effets ind\u00e9sirables qui ont \u00e9t\u00e9 rapport\u00e9s avec l\u2019usage d\u2019un agent qui appartient \u00e0 la m\u00eame classe de m\u00e9dicaments, \u00e0 savoir les inhibiteurs de JAK, mais pris par voie orale. Cet autre m\u00e9dicament sert \u00e0 traiter une forme d\u2019arthrite. Les inhibiteurs de JAK topiques ne sont pas prescrits contre l&rsquo;arthrite. Tous les m\u00e9dicaments sont associ\u00e9s \u00e0 des risques et \u00e0 des bienfaits, qui doivent \u00eatre pass\u00e9s en revue avec le professionnel de la sant\u00e9 prescripteur. Demandez \u00e0 votre professionnel de la sant\u00e9 si ce m\u00e9dicament peut vous convenir.<\/span><\/p>\n<h2>Que faire si ma dermatite atopique ne s\u2019att\u00e9nue pas?<\/h2>\n<p><span style=\"font-weight: 400;\">Si vous pensez que votre DA ne r\u00e9pond pas au traitement, informez-en votre m\u00e9decin. Il se peut que votre plan de traitement doive \u00eatre modifi\u00e9. Un professionnel de la sant\u00e9, tel un dermatologue, peut r\u00e9\u00e9valuer votre maladie ou celle de votre enfant et revoir le plan de traitement.<\/span><span style=\"font-weight: 400;\"> Il n\u2019existe pas de traitement curatif de la DA, mais il y a d\u00e9sormais de nombreux traitements qui peuvent aider les patients.\u00a0<\/span><\/p>\n<p>La Soci\u00e9t\u00e9 canadienne de l\u2019ecz\u00e9ma remercie la D<sup>re<\/sup> Ashley Sutherland (M. Sc., FRCPC) de sa contribution volontaire \u00e0 ce contenu \u00e9ducatif.<\/p>\n<p><span style=\"font-weight: 400;\"><strong>R\u00e9f\u00e9rence<\/strong> : <\/span><span style=\"font-weight: 400;\"><sup>1<\/sup> <\/span><span style=\"font-weight: 400;\">Incyte Corporation (octobre 2024). <\/span><span style=\"font-weight: 400;\">Monographie d\u2019Opzelura<\/span><span style=\"font-weight: 400;\">\u00ae<\/span><span style=\"font-weight: 400;\"> (<\/span><span style=\"font-weight: 400;\">ruxolitinib<\/span><span style=\"font-weight: 400;\">), inhibiteur de Janus kinase (JAK) topique.\u00a0<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Avis de non-responsabilit\u00e9\u00a0: L\u2019information contenue dans cette ressource ne remplace pas les conseils d\u2019un m\u00e9decin et ne doit pas servir d\u2019outil diagnostique. L\u2019information \u00e9tait \u00e0 jour \u00e0 la date de publication. Les interventions, les m\u00e9dicaments et les plans de traitement sont tous associ\u00e9s \u00e0 des risques et \u00e0 des bienfaits. Il est donc important de discuter de ses besoins particuliers ou de ceux de son enfant avec un professionnel de la sant\u00e9 qualifi\u00e9.\u00a0<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apprenez-en plus sur les inhibiteurs de JAK topiques contre la dermatite atopique avec la Dre Ashley Sutherland, dermatologue La Soci\u00e9t\u00e9 canadienne de l\u2019ecz\u00e9ma a demand\u00e9 \u00e0 la Dre\u00a0Ashley Sutherland (M.\u00a0Sc., FRCPC), dermatologue, de nous faire part de son expertise au sujet d\u2019Opzelura\u00ae (ruxolitinib), un inhibiteur de JAK topique, dans le traitement de la dermatite atopique [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53],"tags":[],"class_list":["post-17504","post","type-post","status-publish","format-standard","hentry","category-traitements"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada\" \/>\n<meta property=\"og:description\" content=\"Apprenez-en plus sur les inhibiteurs de JAK topiques contre la dermatite atopique avec la Dre Ashley Sutherland, dermatologue La Soci\u00e9t\u00e9 canadienne de l\u2019ecz\u00e9ma a demand\u00e9 \u00e0 la Dre\u00a0Ashley Sutherland (M.\u00a0Sc., FRCPC), dermatologue, de nous faire part de son expertise au sujet d\u2019Opzelura\u00ae (ruxolitinib), un inhibiteur de JAK topique, dans le traitement de la dermatite atopique [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/\" \/>\n<meta property=\"og:site_name\" content=\"Eczema Society of Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/EczemaSocietyofCanada\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-23T20:22:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-17T20:28:26+00:00\" \/>\n<meta name=\"author\" content=\"support@1dea.ca\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@EczemaSocietyCA\" \/>\n<meta name=\"twitter:site\" content=\"@EczemaSocietyCA\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"support@1dea.ca\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/\"},\"author\":{\"name\":\"support@1dea.ca\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#\\\/schema\\\/person\\\/49d21625952d7bdf0988f82470cacc00\"},\"headline\":\"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)\",\"datePublished\":\"2026-01-23T20:22:08+00:00\",\"dateModified\":\"2026-02-17T20:28:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/\"},\"wordCount\":776,\"publisher\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#organization\"},\"articleSection\":[\"Traitements\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/\",\"url\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/\",\"name\":\"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#website\"},\"datePublished\":\"2026-01-23T20:22:08+00:00\",\"dateModified\":\"2026-02-17T20:28:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/ask-the-doctor-about-opzelura-ruxolitinib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eczemahelp.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#website\",\"url\":\"https:\\\/\\\/eczemahelp.ca\\\/\",\"name\":\"Eczema Society of Canada\",\"description\":\"Educational Resources\",\"publisher\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eczemahelp.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#organization\",\"name\":\"Eczema Society of Canada\",\"url\":\"https:\\\/\\\/eczemahelp.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/eczemahelp.ca\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/eczemahelp.ca\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo.png\",\"width\":362,\"height\":360,\"caption\":\"Eczema Society of Canada\"},\"image\":{\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/EczemaSocietyofCanada\",\"https:\\\/\\\/x.com\\\/EczemaSocietyCA\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/EczemaHelp\",\"https:\\\/\\\/www.instagram.com\\\/eczemasocietyofcanada\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/#\\\/schema\\\/person\\\/49d21625952d7bdf0988f82470cacc00\",\"name\":\"support@1dea.ca\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/eczemahelp.ca\\\/wp-content\\\/litespeed\\\/avatar\\\/97a3c8069c1b8c15f712e101b8d9ab1a.jpg?ver=1776185502\",\"url\":\"https:\\\/\\\/eczemahelp.ca\\\/wp-content\\\/litespeed\\\/avatar\\\/97a3c8069c1b8c15f712e101b8d9ab1a.jpg?ver=1776185502\",\"contentUrl\":\"https:\\\/\\\/eczemahelp.ca\\\/wp-content\\\/litespeed\\\/avatar\\\/97a3c8069c1b8c15f712e101b8d9ab1a.jpg?ver=1776185502\",\"caption\":\"support@1dea.ca\"},\"url\":\"https:\\\/\\\/eczemahelp.ca\\\/fr\\\/author\\\/support1dea-ca\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/","og_locale":"fr_FR","og_type":"article","og_title":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada","og_description":"Apprenez-en plus sur les inhibiteurs de JAK topiques contre la dermatite atopique avec la Dre Ashley Sutherland, dermatologue La Soci\u00e9t\u00e9 canadienne de l\u2019ecz\u00e9ma a demand\u00e9 \u00e0 la Dre\u00a0Ashley Sutherland (M.\u00a0Sc., FRCPC), dermatologue, de nous faire part de son expertise au sujet d\u2019Opzelura\u00ae (ruxolitinib), un inhibiteur de JAK topique, dans le traitement de la dermatite atopique [&hellip;]","og_url":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/","og_site_name":"Eczema Society of Canada","article_publisher":"https:\/\/www.facebook.com\/EczemaSocietyofCanada","article_published_time":"2026-01-23T20:22:08+00:00","article_modified_time":"2026-02-17T20:28:26+00:00","author":"support@1dea.ca","twitter_card":"summary_large_image","twitter_creator":"@EczemaSocietyCA","twitter_site":"@EczemaSocietyCA","twitter_misc":{"\u00c9crit par":"support@1dea.ca","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/#article","isPartOf":{"@id":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/"},"author":{"name":"support@1dea.ca","@id":"https:\/\/eczemahelp.ca\/#\/schema\/person\/49d21625952d7bdf0988f82470cacc00"},"headline":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)","datePublished":"2026-01-23T20:22:08+00:00","dateModified":"2026-02-17T20:28:26+00:00","mainEntityOfPage":{"@id":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/"},"wordCount":776,"publisher":{"@id":"https:\/\/eczemahelp.ca\/#organization"},"articleSection":["Traitements"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/","url":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/","name":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada","isPartOf":{"@id":"https:\/\/eczemahelp.ca\/#website"},"datePublished":"2026-01-23T20:22:08+00:00","dateModified":"2026-02-17T20:28:26+00:00","breadcrumb":{"@id":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eczemahelp.ca\/ask-the-doctor-about-opzelura-ruxolitinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eczemahelp.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)"}]},{"@type":"WebSite","@id":"https:\/\/eczemahelp.ca\/#website","url":"https:\/\/eczemahelp.ca\/","name":"Eczema Society of Canada","description":"Educational Resources","publisher":{"@id":"https:\/\/eczemahelp.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eczemahelp.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/eczemahelp.ca\/#organization","name":"Eczema Society of Canada","url":"https:\/\/eczemahelp.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/eczemahelp.ca\/#\/schema\/logo\/image\/","url":"https:\/\/eczemahelp.ca\/wp-content\/uploads\/2023\/06\/logo.png","contentUrl":"https:\/\/eczemahelp.ca\/wp-content\/uploads\/2023\/06\/logo.png","width":362,"height":360,"caption":"Eczema Society of Canada"},"image":{"@id":"https:\/\/eczemahelp.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EczemaSocietyofCanada","https:\/\/x.com\/EczemaSocietyCA","https:\/\/www.youtube.com\/user\/EczemaHelp","https:\/\/www.instagram.com\/eczemasocietyofcanada\/"]},{"@type":"Person","@id":"https:\/\/eczemahelp.ca\/#\/schema\/person\/49d21625952d7bdf0988f82470cacc00","name":"support@1dea.ca","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/eczemahelp.ca\/wp-content\/litespeed\/avatar\/97a3c8069c1b8c15f712e101b8d9ab1a.jpg?ver=1776185502","url":"https:\/\/eczemahelp.ca\/wp-content\/litespeed\/avatar\/97a3c8069c1b8c15f712e101b8d9ab1a.jpg?ver=1776185502","contentUrl":"https:\/\/eczemahelp.ca\/wp-content\/litespeed\/avatar\/97a3c8069c1b8c15f712e101b8d9ab1a.jpg?ver=1776185502","caption":"support@1dea.ca"},"url":"https:\/\/eczemahelp.ca\/fr\/author\/support1dea-ca\/"}]}},"_links":{"self":[{"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/posts\/17504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/comments?post=17504"}],"version-history":[{"count":6,"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/posts\/17504\/revisions"}],"predecessor-version":[{"id":18821,"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/posts\/17504\/revisions\/18821"}],"wp:attachment":[{"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/media?parent=17504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/categories?post=17504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eczemahelp.ca\/fr\/wp-json\/wp\/v2\/tags?post=17504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}